Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Goodman RS, Lawless A, Woodford R, Fa'ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Johnson DB.
Goodman RS, et al. Among authors: long gv.
JAMA Netw Open. 2023 Aug 1;6(8):e2327145. doi: 10.1001/jamanetworkopen.2023.27145.
JAMA Netw Open. 2023.
PMID: 37535354
Free PMC article.